Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has proved helpful vigilantly but unsuccessfully to create an one-time therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this treatment, CytoDyn has cast its net far and wide both geographically and in terminology of prospective indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be being used is actually an open question.

While CYDY  is actually dawdling, promote opportunities for leronlimab as being a combination treatment in the treatment of multi-drug-resistant HIV happen to be closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of my last few shares. My first CytoDyn article, “CytoDyn: What to be able to Do When It is Too Good To Be True?”, set away all of the following prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan presented such a highly promotional image in the Uptick Newswire employment interview that I came away with an inadequate viewpoint of the business.

Irony of irony, the bad opinion of mine of the company has grown steadily, however, the disappointment has not been financial. 2 years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > 6 bagger yet still disappoints? Therein sits the story; allow me to explain.

CytoDyn acquired its much-storied therapy (which I shall refer to as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor of the therapy as well as reduction of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti-viral activity in HIV infected subjects. Today’s payment of $3.5 huge number of transfers ownership of this technology and also associated intellectual property from Progenics to CytoDyn, and also roughly 25 million mg of majority drug substance…. milestone payments after commencement of a level III clinical trial ($1.5 zillion) as well as the first brand new drug application endorsement ($5 million), and also royalty payments of five percent of net sales upon commercialization.

Since that moment, CytoDyn’s helping nous, Nader Pourhassan [NP] has turned this inauspicious acquisition right into a springboard for CytoDyn to buy a market place cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with multiple indications and numerous therapies, it’s this individual treatments as well as a “broad pipeline of indications” since it places it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a likely advantageous therapy of dozens of indications.

Its opening banner on the site of its (below) shows an active business with diverse interests albeit focused on leronlimab, several disease types, multiple delivering presentations in addition to multiple publications.

Might it all be smoke and mirrors? That is a question I have been asking myself from the really beginning of the interest of mine in this business. Judging by way of the multiples of a huge number of several remarks on listings accessible via Seeking Alpha’s CytoDyn Summary page, I’m much from alone in this particular question.

CytoDyn is a classic battleground, or some may say cult inventory. Its adherents are fiercely shielding of its prospects, quick to label some bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *